Bridging the gap between innovation and capital
ALS Investment Fund
ALS or neurodegenerative disease therapy-focused
Program
The ALS Investment Fund is a venture capital fund that invests in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus on ALS. Its portfolio and past investments include Amylyx, Verge Genomics, Prilenia, QurAlis, Bloom Science, VectorY, ProJenX, and more.
Event
LaunchBio, Browne Consulting, and Silicon Valley Bank, a division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with the ALS Investment Fund.
They invest in biotech companies developing drugs in a specialized area of disease: neurodegeneration, with a particular focus on ALS. Neurodegeneration is the leading cause of death and disability, with 1 in 5 people getting a neurodegenerative disease. 1 in 350 people will get ALS – as many as Multiple Sclerosis
Applications will be selected based on meeting the following criteria:
Geography
Focus on US and Europe
Company type
ALS or neurodegenerative disease therapy-focused.
Modalities of Interest
- Small molecule
- Biologics
- CRISPR-based therapies
- Gene therapies
- Microbiome-based therapies
- Protein-based therapies (e.g. antibody-drug conjugates, peptide therapeutics, protein degraders)
- RNA-based therapeutics
Stage
Sweet spot is Series A with companies entering or close to entering Clinical Trials, with a desire to fund through Proof-of-Concept / Phase II.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Browne Consulting and Silicon Valley Bank, a division of First Citizens Bank.